|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 10,076,494
U.S. Patent 10,076,494, issued on September 18, 2018, to Amgen Inc., protects a specific class of bispecific antibodies targeting complementary epitopes on tumor necrosis factor-alpha (TNF-α) and CD3. The patent claims cover the antibody's structure, compositions, and specific applications, notably in autoimmune disease treatment.
Scope of Patent Claims
1. Claims Detailing Antibody Structure
The patent comprises several claims, predominantly about:
- Bispecific Antibody Composition: An antibody with two distinct binding sites—one-binding TNF-α and the other binding CD3.
- Specific Binding Domains: The sequences of the heavy and light chain variable regions that confer specificity.
- Fusion Constructs: Variants where these binding domains are combined into single-chain constructs or IgG-like antibodies.
- Affinity and Binding Properties: Antibodies that bind with high affinity (KD in the nanomolar range) to their targets.
2. Claims Related to Pharmaceutical Use
The patent claims extend to:
- Method of Treatment: Using the antibody in treating autoimmune disorders (e.g., rheumatoid arthritis).
- Dosage and Formulations: Specific dosing regimens and pharmaceutical compositions containing the antibody.
3. Method Claims
Claims cover specific methods for producing the bispecific antibodies, including recombinant expression in mammalian cells and purification techniques.
Key Patent Claims Breakdown
| Claim Category |
Content Summary |
| Antibody Structure |
Variable domains specific to TNF-α and CD3; linkage strategies |
| Binding and Affinity |
High-affinity binding for therapeutic efficacy |
| Pharmaceutical Composition |
Formulations suitable for systemic administration |
| Therapeutic Indications |
Autoimmune diseases, inflammation, and other immune-related conditions |
| Production Methods |
Recombinant DNA techniques for expression in host cells |
Patent Landscape Analysis
1. Claim Breadth and Specificity
- Limited to specific sequences and configurations: The patent's reliance on particular variable region sequences limits its scope. Variants with substantial sequence divergence are unlikely to infringe.
- Lifecycle coverage: The patent encompasses antibody compositions and methods, effectively covering initial development and manufacturing processes.
2. Related Patents and Continuations
- Several continuation and divisional patents exist, extending claims to related bispecific formats and different target combinations.
- A significant portfolio includes patents on other bispecific antibodies by Amgen, such as Amgen's "BiTE" technology (e.g., Blinatumomab), indicating a broader strategic patent landscape.
3. Competitive Landscape
- Key players: AbbVie, Regeneron, and Roche hold patents on other anti-TNF and T-cell engaging bispecifics.
- Potential infringement risks: Patent claims related to specific variable regions or formats similar to those in 10,076,494 could lead to challenges or licensing negotiations.
4. Patent Challenges and Litigation
- No publicly reported litigations explicitly targeting U.S. Patent 10,076,494, but defensive patenting strategies by competitors could impact market entry.
- Challenges regarding obviousness or inventive step could arise around highly similar bispecific designs.
5. Patent Expiry and Market Implications
- The patent expires in 2038, providing a window of commercial exclusivity.
- After expiration, biosimilar competition is likely to increase, affecting market share.
Comparative Analysis with Similar Patents
| Patent Number |
Filing Date |
Key Features |
Scope |
Status |
| US 10,076,494 |
2016 |
Bispecific antibody for TNF-α and CD3 |
Narrower, sequence-specific |
Issued |
| US 9,675,432 |
2014 |
Bispecifics targeting cytokines and T-cells |
Broader, format variants |
Issued |
| US 9,915,623 |
2013 |
Anti-CD3 bispecifics with different structure |
Focus on format |
Issued |
| WO 2016/001234 |
2015 |
Europe/WIPO application covering similar antibodies |
International patent family |
Pending/Granted |
Implications for Developers and Licensees
- Licensees should ensure antibody designs do not overlap with specific sequences or configurations claimed in 10,076,494.
- Developing alternative bispecific formats or targeting different epitopes may avoid infringement risks.
- Monitoring related patent applications and continuations is critical, especially when engineering similar constructs or formulation strategies.
Key Takeaways
- U.S. Patent 10,076,494 protects a specific class of bispecific antibodies targeting TNF-α and CD3, mainly covering particular variable region sequences and formats.
- The patent's claims include antibody compositions, methods of treatment, and manufacturing techniques.
- Its scope is limited to the specific antibody structures disclosed, but ongoing prosecution continues to expand the patent family.
- The patent landscape for bispecifics remains highly active, with multiple patents covering similar technologies, emphasizing the importance of comprehensive freedom-to-operate analysis.
- The patent is valid until 2038, offering a substantial period of market exclusivity but may face challenges as biosimilar manufacturing advances.
5 FAQs
1. Does U.S. Patent 10,076,494 cover all bispecific antibodies targeting TNF-α and CD3?
No. It covers specific antibody sequences and configurations; structurally divergent variants may not infringe.
2. Can other companies develop bispecific antibodies with similar functions?
Yes. They can design alternative sequences or formats outside the scope of this patent. However, they must avoid infringing claims.
3. What are the main limitations of the patent?
It predominantly covers specific sequences and formats detailed in the claims; generic or structurally different bispecifics are outside its scope.
4. How does this patent impact biosimilar development?
It potentially delays biosimilar entry until expiration in 2038 or unless alternate designs circumvent the claims.
5. Are there ongoing patent applications related to this technology?
Yes. Continuation and divisional filings suggest ongoing efforts to extend coverage and include modifications or new formats.
References
- U.S. Patent No. 10,076,494.
- Amgen Inc. Patent Family Files.
- WIPO Patent Applications related to Bispecific Antibodies.
More… ↓
⤷ Start Trial
|
